drugset / Trial / NCT07392866
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma
Timeline
- Start
- 2026-03-01
- Primary completion
- 2030-03-01
- Completion
- 2030-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Oxaliplatin injection | Unknown | 85 mg/m2 | Intravenous |
| Comparator | Regorafenib | Small molecule | 160 mg | Oral |
| Subject | SH006 | Unknown | 15 mg/kg | Intravenous |